
Viatris (VTRS) Stock Forecast & Price Target
Viatris (VTRS) Analyst Ratings
Bulls say
Viatris is viewed favorably because the Pacira acquisition expands its U.S. branded pain franchise, adds roughly 340 FTEs of commercial infrastructure, and strengthens launch execution for fast-acting meloxicam ahead of the Dec. 27 PDUFA. The deal also improves the margin profile, with Pacira’s ~80% gross margin, while supporting forecasts of 2027 revenue of $15.75B and EBITDA of $5.04B, alongside about $50M in annual savings by YE28. More broadly, the market may be underestimating Viatris’s improving growth mix from generics, biosimilars, legacy brands, and pipeline assets such as fast-acting meloxicam, selatogrel, and cenerimod, which could support a rerating as execution improves.
Bears say
Viatris is viewed negatively because its core business remains heavily exposed to commoditized generics, volume-based procurement in Greater China, and structural price reductions in JANZ, all of which can pressure revenue and margins. Its growth depends on execution around new products and pipeline assets, yet commercial uptake for launches like Journavx may be constrained by payer access, reimbursement friction, and hospital budget resistance, while manufacturing compliance issues at Indore or Nashik could further disrupt supply and raise costs. The pipeline also carries meaningful binary risk, as Selatogrel underpins a $1Bn-plus peak sales estimate, Cenerimod already missed a Phase 2b primary endpoint, and acquisition or integration risk around PCRX adds another layer of uncertainty.
This aggregate rating is based on analysts' research of Viatris and is not a guaranteed prediction by Public.com or investment advice.
Viatris (VTRS) Analyst Forecast & Price Prediction
Start investing in Viatris (VTRS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Viatris (VTRS) Forecast
Viatris (VTRS) Analyst Forecast & Price Prediction
Start investing in Viatris (VTRS)
Order type
Buy in
Order amount
Est. shares
0 shares